HC Wainwright & Co. reiterates Neutral rating on Aldeyra Therapeutics, $2 price target
HC Wainwright & Co. reiterated their Neutral rating on Aldeyra Therapeutics's stock with a price target of $2.00.The price target implies an upside of 51.5% from the Sep 29 close of $1.32.Key takeaways from the analyst noteRegulatory Uncertainty: There remains a lack of definitive assurance from th…